Table 1. Baseline Characteristics of Participants in the Bone Trial.
| Characteristic | Testosterone (n = 110) | Placebo (n = 101) |
|---|---|---|
| Age, mean (SD), y | 72.3 (6.3) | 72.4 (5.5) |
| Race, No. (%) | ||
| White | 93 (84.5) | 88 (87.1) |
| African American | 6 (5.5) | 4 (4.0) |
| Other | 11 (10.0) | 9 (8.9) |
| Concomitant conditions, mean (SD) | ||
| BMI, mean (SD) | 30.7 (3.7)a | 31.8 (3.1) |
| Alcohol use, mean (SD), No. drinks/wk | 2.5 (3.5)a | 4.0 (5.3) |
| Smoking, No. (%) | ||
| Current smoker | 6 (5.5) | 7 (6.9) |
| Ever smoker | 70 (63.6) | 72 (71.3) |
| Diabetes | 43 (39.1) | 40 (39.6) |
| Serum steroid hormone, mean (SD) | ||
| Total testosterone, ng/dL | 229.6 (65.3) | 238.8 (64.0) |
| Free testosterone, pg/mL | 61.2 (20.0) | 64.5 (21.1) |
| Estradiol, pg/mL | 20.5 (6.7)a | 22.4 (6.4) |
| DXA areal BMD, mean (SD), g/cm2 | ||
| Lumbar spine | 1.2 (0.2) | 1.2 (0.2) |
| Total hip | 1.0 (0.2) | 1.0 (0.1) |
| Femoral neck | 0.8 (0.1) | 0.8 (0.1) |
| DXA BMD T-score,b mean (SD) | ||
| Lumbar spine | 1.3 (1.8) | 1.2 (1.8) |
| Total hip | 0.7 (1.2) | 0.6 (1.2) |
| Femoral neck | -0.3 (1.1) | -0.3 (1.2) |
Abbreviations: BMD, bone mineral density; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); DXA, dual-energy x-ray absorptiometry.
SI conversion factors: To convert testosterone to nanomoles per liter, multiply by 0.0347; to convert free testosterone to picomoles per liter, multiply by 3.47; to convert estradiol to picomoles per liter, multiply by 3.67.
a
P < .05 compared with placebo (t test).
b
Calculated from young female referent database.